title: Wyburn-Mason Syndrome Associated With Cutaneous Reactive Angiomatosis and Central Retinal Vein Occlusion.
abstract: Retinal venous occlusive events are a rare complication of arteriovenous malformations of the retina found in Wyburn-Mason syndrome. The authors present a case of a 28-year-old man diagnosed with Wyburn-Mason syndrome and cutaneous reactive angiomatosis, a reactive angioproliferative disorder induced by vascular occlusion. He developed a central retinal vein occlusion complicated by macular edema and received treatment with intravitreal bevacizumab, which led to resolution of the edema. To the best of the authors' knowledge, this is the first report of an anti- vascular endothelial growth factor agent employed as an effective treatment for macular edema in the setting of Wyburn-Mason syndrome. The association between Wyburn-Mason syndrome and cutaneous reactive angiomatosis is also a novel finding.
authors.forename: Alison B
authors.initials: AB
authors.lastname: Callahan
authors.forename: Dimitra
authors.initials: D
authors.lastname: Skondra
authors.forename: Magdalena
authors.initials: M
authors.lastname: Krzystolik
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Yonekawa
authors.forename: Dean
authors.initials: D
authors.lastname: Eliott
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000798:Angiomatosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D001164:Arteriovenous Fistula / Q000150:complications* / Q000175:diagnosis; D000068258:Bevacizumab / Q000627:therapeutic use*; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D020752:Neurocutaneous Syndromes / Q000150:complications* / Q000175:diagnosis; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D012871:Skin Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab